Ultrasound remotely triggers immune cells to attack tumors in mice without toxic side effects

A new cancer immunotherapy pairs ultrasound with specially engineered CAR T cells to destroy malignant tumors while sparing normal tissue. The new experimental therapy significantly slowed down the growth of solid cancerous tumors in mice.

Combined approach could boost breast cancer immunotherapy, study suggests

Activating an immune signaling pathway best known for fighting viral and bacterial infections can boost the ability of genetically engineered T cells to eradicate breast cancer in mice, according to a new study by researchers at the University of North Carolina. The study, to be published December 31 in the Journal of Experimental Medicine (JEM), suggests that CAR T cells, which are already used to treat certain blood cancers in humans, may also be successful against solid tumors if combined with other immunotherapeutic approaches.

NCCN: What People with Cancer and their Caregivers Need to Know about CAR T-Cell Therapy

The National Comprehensive Cancer Network (NCCN) has published a new NCCN Guidelines for Patients: Immunotherapy Side Effects focused on chimeric antigen receptor (CAR) T-cell therapy. This is book two in a series that includes another book on irAEs focused on immune checkpoint inhibitors.